Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
about
Targeted Delivery of Proteasome Inhibitors to Somatostatin-Receptor-Expressing Cancer Cells by Octreotide ConjugationPeptide analogs in the therapy of prostate cancer.Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release.Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Somatostatin analogs and radiopeptides in cancer therapy.Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice.Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Supramolecular filaments containing a fixed 41% paclitaxel loading.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Receptor-mediated tumor targeting based on peptide hormones.Peptide-mediated targeted drug delivery.Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectivesDrug delivery and release systems for targeted tumor therapy.Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity.Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.Design, Synthesis, and Biological Evaluations of Asymmetric Bow-Tie PAMAM Dendrimer-Based Conjugates for Tumor-Targeted Drug Delivery.
P2860
Q27702302-5EE377CD-D69D-4FB8-BDA7-9668DC6E93CEQ34057795-6B2D62FC-6B81-4B63-8CD3-7406891CB301Q34117185-C855F7E2-BD4A-4F14-9A21-4108D607E665Q34182483-66C909EA-0D39-48D9-8337-44A20FC1496FQ34519166-71AE7802-56B6-4FED-8074-5EB0A3D3BF3AQ34565264-63A3EBE9-01A1-4013-9DE0-2EEE0F07B61CQ34772221-D05AC61C-2DEF-4FFE-A138-3AC61041DA51Q34972896-468F292A-8238-49D2-B542-951D851A7969Q34979199-34526E75-48AD-4F78-9B5D-DF98B0991399Q35180952-09EF6C9B-3F2B-4F55-B068-A611FD6CFF9DQ35199203-BD195130-AC35-45C9-ADAF-FB70DC0865B4Q36512574-1879D4DD-7448-4DCE-B7C6-CAC911BBB0B4Q36619058-2E3F6F28-5750-4CB8-BBAA-370A8C9E4067Q36734495-D08765F4-872D-4B04-BE12-8A53435324DDQ36748502-09AE1F95-9BAC-44C8-AABE-DE30197F2B9EQ36936170-848C9718-25BF-487F-B94B-A7FD7287DF70Q37083440-1B7B4C05-57F4-4AD9-A8C3-3ADC8CF91045Q37196815-2E46AD4D-725E-4E1E-8235-C48D105F2BFAQ37323454-EEFC8209-A955-4739-AAEF-49CF15449EFCQ37483944-9F211DE7-6F1E-4788-830A-E4D8FEF70208Q37579225-EFF5CE33-76B7-489E-A547-167EF037787CQ37641368-CB7740A6-C239-4C53-B190-D5DB19B235DEQ37785045-A5DDD6BB-25A3-49A5-9DE6-B792373266A4Q38216009-B0F8352F-EF99-4CE7-B5FB-4CE6ACD86CA0Q38363691-79B20BA0-9D5C-4BBF-9041-2853788F24BEQ38757086-EC3A7B58-BEB6-4232-BF66-6CB0778109F8Q39428786-2782442A-0967-4964-9C8A-51DE8CEA8BB6Q40778582-8E21DEA3-BC50-49A4-83F2-7827644EC931Q42795202-1CECD5C6-4A1C-4C67-863B-48A749DEA28BQ47913323-EB7DB636-963A-4161-A0BD-2172665EACFEQ50865530-F5B69066-CC24-4BBA-823D-DD5064E5170CQ54957223-09D4A69E-CF28-4F29-82D2-E861199C5881
P2860
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Synthesis and biological evalu ...... ative, 2-pyrrolinodoxorubicin.
@ast
Synthesis and biological evalu ...... ative, 2-pyrrolinodoxorubicin.
@en
type
label
Synthesis and biological evalu ...... ative, 2-pyrrolinodoxorubicin.
@ast
Synthesis and biological evalu ...... ative, 2-pyrrolinodoxorubicin.
@en
prefLabel
Synthesis and biological evalu ...... ative, 2-pyrrolinodoxorubicin.
@ast
Synthesis and biological evalu ...... ative, 2-pyrrolinodoxorubicin.
@en
P2093
P2860
P356
P1476
Synthesis and biological evalu ...... vative, 2-pyrrolinodoxorubicin
@en
P2093
K Szepesházi
P2860
P304
P356
10.1073/PNAS.95.4.1794
P407
P577
1998-02-01T00:00:00Z